作者
F Franchi, F Rollini, L Ortega Paz, L Been, S Giordano, M Galli, G Ghanem, H Garabedian, T Al Saleh, A Rivas, AM Pineda, S Suryadevara, D Soffer, MM Zenni, DJ Angiolillo
发表日期
2023/11
期刊
European Heart Journal
卷号
44
期号
Supplement_2
页码范围
ehad655. 2864
出版商
Oxford University Press
简介
Background
Cangrelor is an intravenous P2Y12 inhibitor used in patients undergoing coronary intervention (PCI). Preliminary studies have shown the potential for a drug-drug interaction (DDI) when transitioning from cangrelor to oral P2Y12 inhibition with prasugrel. However, to date this has not been prospectively tested in patients undergoing PCI.
Purpose
To rule out a DDI when cangrelor and prasugrel are concomitantly administered in patients undergoing PCI.
Methods
SWAP-6 is a prospective, randomized, 3-arm, open-label, pharmacokinetic (PK) and pharmacodynamic (PD) study conducted in patients undergoing PCI (n=77). Patients were randomized to either a) prasugrel only administered at the start of PCI; b) cangrelor plus prasugrel concomitantly administered at the start of PCI; c) cangrelor administered at the start of PCI plus prasugrel …
学术搜索中的文章
F Franchi, F Rollini, L Ortega Paz, L Been, S Giordano… - European Heart Journal, 2023